Management of an Imipenem-resistant Acinetobacter Baumannii Alert in a French University Hospital

NCT06173440 | Unknown

• 1 other identifier: 7588
• Study Type: observational
• Target: 148
• Locations: 1 country
• Sites: 1

Brief Summary

Colonization with imipenem-resistant Acinetobacter baumannii (IBA) is an unfavorable event for the patient, especially in intensive care. Indeed, it exposes the patient to the risk of developing serious infections, extremely difficult to treat. ABRI is a particularly resistant bacterium in the environment. When an ABRI epidemic occurs in a department as central to the hospital as a surgical resuscitation department, the control of such an event can be extremely complex. There are few clear and detailed descriptions in the literature of how to manage this type of outbreak, let alone an ABRI outbreak of this magnitude.

Conditions

Acinetobacter Baumannii

Keywords

Acinetobacter baumannii; Imipenem-resistant

Outcome Measures

Primary Outcomes (1)

• Retrospective description of the management of an imipenem-resistant Acinetobacter baumannii outbreak that occurred from 2015 to 2019 in a surgical intensive care unit

  Through study completion, an average of 5 months

Eligibility Criteria

• Age: 18 Years+
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)
• Sampling Method: Non-Probability Sample

Study Population

Major subject (≥18 years old) having been hospitalized in the surgical resuscitation service of Hautepierre during the ABRI epidemic, between 01/05/2015 and 01/01/2019 inclusive and having been colonized and/or infected by ABRI

You may qualify if:

• Major subject (≥18 years old)
• Patient having been hospitalized in the surgical resuscitation service of Hautepierre during the ABRI epidemic, between 01/05/2015 and 01/01/2019 inclusive and having been colonized and/or infected by ABRI (according to bacteriological results transmitted to the hygiene service).
• Subject having given his/her agreement, after information, for the reuse of his/her data for the purpose of this research

You may not qualify if:

• Subject having expressed his opposition to participate in the study
• Subject under guardianship or curatorship
• Subject under legal protection

Sponsors & Collaborators

• University Hospital, Strasbourg, France: lead

Study Sites (1)

Service Equipe opérationnelle d'hygiène - CHU de Strasbourg - France

Strasbourg, 67091, France

RECRUITING

Central Study Contacts

Stéphanie DEBOSCKER, MD

CONTACT

33 3 69 55 03 10; stephanie.deboscker@chru-strasbourg.fr

Study Design

• Study Type: observational
• Observational Model: CASE ONLY
• Time Perspective: RETROSPECTIVE
• Sponsor Type: OTHER
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: November 7, 2022
• First Posted: December 15, 2023
• Study Start: January 1, 2020
• Primary Completion: December 1, 2023
• Study Completion: December 1, 2023
• Last Updated: December 15, 2023

Record last verified: 2023-12

Locations

FR (1)